Phase II study to evaluate the efficacy and safety of mirogabalin for CIPN in patients with gastrointestinal cancer.
收藏NIAID Data Ecosystem2026-03-14 收录
官方服务：
资源简介：
Interventions: Initial dose of mirogabalin orally twice daily, then titrated at intervals of at least 1 week to a maintenance dose orally twice daily. Primary outcome(s): Change in 24-hour pain (including numbness) average NRS (Numeric Rating Scale) from the start of mirogabalin administration to 6 weeks. Study Design: Single arm Non-randomized
创建时间：
2022-12-15
